Anticoagulants Market to Reach USD 65 Billion by 2031 at CAGR of 8.04% Driven by Rising CVD Cases and Geriatric Population

The global anticoagulants market, valued at USD 30 billion in 2021, is poised to witness robust growth, reaching USD 65 billion by 2031, expanding at a CAGR of 8.04% over the forecast period. This surge is driven by the increasing prevalence of cardiovascular diseases (CVDs), such as atrial fibrillation and deep vein thrombosis, as well as the growing elderly population worldwide, which is more prone to blood clots and related complications.

Historical Analysis and Growth Catalysts

Between 2016 and 2020, the anticoagulants market grew steadily at a CAGR of 5%. This was largely supported by healthcare infrastructure improvements, especially in emerging nations, where governments prioritized modernizing services and expanding access to quality care.

Moving into the next decade, increasing awareness of heart conditions, a sedentary lifestyle leading to obesity, and a shift from traditional drugs like warfarin to novel oral anticoagulants (NOACs/DOACs) are all major growth factors. Moreover, pharmaceutical companies are boosting R&D pipelines, investing in clinical trials, and launching improved formulations to tap into growing market opportunities.

Browse For Full Report: https://www.factmr.com/report/4335/anticoagulants-market

Atrial Fibrillation: A Major Demand Driver

Atrial fibrillation (AF) has emerged as a key factor influencing anticoagulant sales. It is estimated that 6-12 million Americans will suffer from AF by 2050, while Europe may witness over 17 million cases by 2060. AF significantly increases stroke risk and has a high economic and mortality burden.

As per the National Center for Biotechnology Information, over 3 million new AF cases were recorded in 2017, reflecting a 31% increase in incidence compared to 1997. The global AF prevalence reached 37.5 million cases, up 33% over two decades, particularly in countries with moderate socio-demographic indices. This trend will likely intensify demand for anticoagulants worldwide.

Regional Insights

United States: Strong Growth Backed by Obesity and Awareness

In 2020, the U.S. led the anticoagulants market due to widespread obesity and increased public awareness. With the CDC reporting a 42.4% obesity rate, this condition remains a prominent risk factor for CVDs. The U.S. market is anticipated to grow at a CAGR of 7.5% through 2031, driven by access to advanced healthcare and expanding insurance coverage.

Japan: Geriatric Population Fueling Demand

Japan, with 28% of its population aged 65 or older in 2020, is another major market. Elderly individuals often undergo procedures like knee and hip replacements or suffer from conditions like venous thromboembolism and AF, necessitating long-term anticoagulation therapy. Japan is expected to command 45% of the East Asian market share, with consistent demand driven by demographic trends.

China: Fastest-Growing Market

China is expected to register the highest CAGR of over 8% by 2031. With 4 million annual CVD-related deaths, the country is pushing for increased use of preventive measures like anticoagulants. Improved surgical care and better diagnostics are also playing a crucial role in market expansion.

Category Analysis

NOAC/DOAC Factor X Inhibitors Dominate Drug Class

Among drug classes, NOACs/DOACs accounted for over 50% of demand in 2019 and are likely to retain dominance. These drugs-such as apixaban, rivaroxaban, dabigatran, edoxaban, and betrixaban-are preferred due to benefits including predictable pharmacokinetics, fewer dietary restrictions, and reduced monitoring requirements compared to warfarin.

Hospital Pharmacies Hold Largest Distribution Share

Hospital pharmacies contribute nearly 49.2% of total anticoagulant sales, as they are central to managing surgeries and complex medical conditions where embolism risks are high. Given their role in acute care, hospitals remain the primary channel for anticoagulant distribution.

Want a Sample Before Buying? Download Free Sample: https://www.factmr.com/connectus/sample?flag=S&rep_id=4335

Competitive Landscape

The anticoagulants market is highly fragmented, with major players focusing on strategic collaborations, new product approvals, and support programs for patient affordability.

Bristol-Myers Squibb and Pfizer retained patent protection for Eliquis® (Apixaban) in a U.S. court ruling in 2020, strengthening their foothold in the market.
Boehringer Ingelheim gained EMA approval for Pradaxa® (dabigatran etexilate) in pediatric VTE treatment in November 2020, expanding its product use.

Key companies operating in the global anticoagulants market include:

Bayer AG
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Company Ltd.
Sanofi SA
Johnson & Johnson

With global trends favoring advanced cardiac care, rising surgical volumes, and a growing aging population, the anticoagulants market is on a solid growth trajectory, poised to more than double in size by 2031. Innovation in drug delivery, combined with expanding online and hospital pharmacy channels, will further solidify the industry's upward path.

Check out More Related Studies Published by Fact.MR Research:

Methylisothiazolinone Market: https://www.factmr.com/report/3934/methylisothiazolinone-market

Refrigeration Valves Market: https://www.factmr.com/report/3943/refrigeration-valves-market

Felling Heads Market: https://www.factmr.com/report/3967/felling-heads-market

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team : sales@factmr.com

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

This release was published on openPR.